| Dr Robert Mathew Hein, MD | |
|
4307 Portales Ct, Arlington, TX 76016-3424 | |
| (817) 300-3985 | |
| Not Available |
| Full Name | Dr Robert Mathew Hein |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 4307 Portales Ct, Arlington, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215148838 | NPI | - | NPPES |
| Entity Name | Medplus Physician Group Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194345959 PECOS PAC ID: 9436513256 Enrollment ID: O20230913000773 |
News Archive
About 1 billion people around the world suffer from hypertension. The molecular mechanisms of this disease, its diagnosis and treatment will be the focus of a lecture series at the American Society for Biochemistry and Molecular Biology's annual meeting in Anaheim, Calif. The talks will take place from Monday, May 26 through Wednesday, April 28 in room 304C of the Anaheim Convention Center.
PharmaJet Inc. has become the first and only needle-free injection company to receive Performance, Quality and Safety (PQS) pre-qualified certification from the World Health Organization (WHO).
Scientists at the University of Liverpool are leading a -1.5 million project to study `immunoglobulin', a type of drug which has been shown to ease complex regional pain syndrome (CRPS).
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.
› Verified 9 days ago
| Entity Name | Wellness Elite Health Partners, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841973146 PECOS PAC ID: 6002260197 Enrollment ID: O20230922001938 |
News Archive
About 1 billion people around the world suffer from hypertension. The molecular mechanisms of this disease, its diagnosis and treatment will be the focus of a lecture series at the American Society for Biochemistry and Molecular Biology's annual meeting in Anaheim, Calif. The talks will take place from Monday, May 26 through Wednesday, April 28 in room 304C of the Anaheim Convention Center.
PharmaJet Inc. has become the first and only needle-free injection company to receive Performance, Quality and Safety (PQS) pre-qualified certification from the World Health Organization (WHO).
Scientists at the University of Liverpool are leading a -1.5 million project to study `immunoglobulin', a type of drug which has been shown to ease complex regional pain syndrome (CRPS).
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Mathew Hein, MD 4307 Portales Ct, Arlington, TX 76016-3424 Ph: (817) 300-3985 | Dr Robert Mathew Hein, MD 4307 Portales Ct, Arlington, TX 76016-3424 Ph: (817) 300-3985 |
News Archive
About 1 billion people around the world suffer from hypertension. The molecular mechanisms of this disease, its diagnosis and treatment will be the focus of a lecture series at the American Society for Biochemistry and Molecular Biology's annual meeting in Anaheim, Calif. The talks will take place from Monday, May 26 through Wednesday, April 28 in room 304C of the Anaheim Convention Center.
PharmaJet Inc. has become the first and only needle-free injection company to receive Performance, Quality and Safety (PQS) pre-qualified certification from the World Health Organization (WHO).
Scientists at the University of Liverpool are leading a -1.5 million project to study `immunoglobulin', a type of drug which has been shown to ease complex regional pain syndrome (CRPS).
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.
› Verified 9 days ago
Dr. Thomas Joseph Miller, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 3600 Matlock Rd Ste 102, Arlington, TX 76015 Phone: 817-467-9096 Fax: 817-472-9338 | |
John Paul Hood, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6201 Matlock Rd, # 139, Arlington, TX 76002 Phone: 817-467-7373 Fax: 817-472-7794 | |
Dennis E Poquiz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2309 W Green Oaks Blvd, Arlington, TX 76016 Phone: 817-496-4957 Fax: 817-496-3783 | |
Dr. Donna B Baker, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1300 S Fielder Rd, Arlington, TX 76013 Phone: 817-277-2221 | |
Chi Ha Vu, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1050 W Arkansas Ln Ste 150, Arlington, TX 76013 Phone: 817-702-1100 Fax: 817-702-4801 | |
Dr. Sherley Aramath, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2415 Matlock Rd, Arlington, TX 76015 Phone: 817-677-2444 | |
Bruce A Henry, M.D.,P.A. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2001 Se Green Oaks Blvd Ste 100, Arlington, TX 76018 Phone: 817-466-7412 Fax: 817-466-7493 |